Measuring Fluid Buildup in Cancer Patients
The goal of this study is to improve the monitoring of fluid retention in cancer patients. The main question it aims to answer is: Can segmental bioelectrical impedance analysis be used to monitor local fluid retention (edema) in cancer patients? We will include: * Breast cancer patients with fluid and or lymph retenti
| Condition(s) | Cancer, Oedema, Bioelectrical Impedance, Lymphoedema, Chemotherapy, Radiotherapy, Fluid Balance |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | The goal of this study is to improve the monitoring of fluid retention in cancer patients. The main question it aims to answer is: Can segmental bioelectrical impedance analysis be used to monitor local fluid retention (edema) in cancer patients? We will include: * Breast cancer patients with fluid and or lymph retention in one or both arms after radiotherapy (outpatients) * Cancer patients with fluid retention in one or both legs after chemotherapy (hospitalized) Participants will: * Have measurements taken using bioelectrical impedance * Provide blood samples and 24-hour urine collection * Weight monitorering * Complete diet and fluid registration (inclusive enteral and parenteral) * Have clinical palpatory and measurement assessment of oedema. |
| Who can participate | Inclusion Criteria (Outpatient breast cancer patients with lymphoedema after radiotherapy): * Habile * Must be able to speak and read Danish * Has received/is receiving radiotherapy due to breast cancer within the last 6 months * Is being followed in the Oncology Outpatient Clinic at Aalborg University Hospital * Age ≥ 18 years * Visible lymphoedema in at least one upper extremity Inclusion Criteria (Hospitalized cancer patients with peripheral oedema in one or both lower extremities after chemotherapy): * Habile * Must be able to speak and read Danish * Has received/is receiving chemotherapy due to cancer within the last 2 months * Hospitalised in the Oncology Ward at Aalborg University Hospital * Estimated length of hospital stay of at least 6 days * Age ≥ 18 years * Visible peripheral o |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Jens Rikardt Andersen |
| Locations | Aalborg, The North Denmark Region, Denmark |
| Start date | 2026-02-01 |
| NCT ID | NCT07443618 |
| Official listing | https://clinicaltrials.gov/study/NCT07443618 |